Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
INC Research Holdings Inc (INCR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/01/2025: INCR (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit 6.26% | Avg. Invested days 40 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 12/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 81.22M USD | Price to earnings Ratio - | 1Y Target Price 33.56 |
Price to earnings Ratio - | 1Y Target Price 33.56 | ||
Volume (30-day avg) - | Beta 0.58 | 52 Weeks Range 1.17 - 2.62 | Updated Date 06/29/2025 |
52 Weeks Range 1.17 - 2.62 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -28.39% | Operating Margin (TTM) -86.82% |
Management Effectiveness
Return on Assets (TTM) -7.09% | Return on Equity (TTM) -17.03% |
Valuation
Trailing PE - | Forward PE 6.94 | Enterprise Value 120187421 | Price to Sales(TTM) 0.34 |
Enterprise Value 120187421 | Price to Sales(TTM) 0.34 | ||
Enterprise Value to Revenue 1.71 | Enterprise Value to EBITDA 5.29 | Shares Outstanding 54512600 | Shares Floating 27296363 |
Shares Outstanding 54512600 | Shares Floating 27296363 | ||
Percent Insiders 30.2 | Percent Institutions 5.38 |
Upturn AI SWOT
INC Research Holdings Inc
Company Overview
History and Background
INC Research Holdings Inc. merged with inVentiv Health in 2017 to form Syneos Health (SYNH). INC Research was founded in 1997 as a clinical research organization (CRO). It grew through acquisitions and organic expansion before its merger.
Core Business Areas
- Clinical Development: Provides comprehensive clinical development services, including clinical trial management, data management, biostatistics, and medical writing.
- Commercial Solutions: Offers commercialization services to pharmaceutical and biotechnology companies, including market access, medical affairs, and sales solutions.
Leadership and Structure
Before merging, INC Research was led by its CEO, Alistair Macdonald. The organizational structure consisted of various business units focused on specific therapeutic areas and service offerings.
Top Products and Market Share
Key Offerings
- Clinical Trial Management: Manages clinical trials for pharmaceutical and biotechnology companies across various therapeutic areas. Market share data is not readily available at the INC Research level due to its combination with inVentiv Health. Competitors include IQVIA, Labcorp, and PPD (now part of Thermo Fisher Scientific).
- Data Management and Biostatistics: Provides data management and biostatistical services for clinical trials, including data collection, analysis, and reporting. Market share data is not readily available. Competitors include IQVIA, Labcorp, and PPD.
Market Dynamics
Industry Overview
The CRO industry is experiencing growth due to increasing R&D spending by pharmaceutical and biotechnology companies, as well as the complexity of clinical trials.
Positioning
Before the merger, INC Research was a mid-sized CRO known for its focus on specific therapeutic areas and its strong relationships with biopharmaceutical companies. Syneos Health now competes on a larger scale.
Total Addressable Market (TAM)
The global CRO market is estimated to be around $70-80 billion. Syneos Health is positioned to capture a significant portion of this TAM.
Upturn SWOT Analysis
Strengths
- Strong therapeutic area expertise
- Established relationships with biopharmaceutical companies
- Global presence
- Comprehensive service offerings
Weaknesses
- Integration challenges post-merger (relevant post-2017 merger with inVentiv)
- Competition from larger CROs
- Reliance on pharmaceutical and biotechnology R&D spending
- Limited Pricing power
Opportunities
- Growth in emerging markets
- Increasing complexity of clinical trials
- Adoption of new technologies
- Strategic partnerships
Threats
- Economic downturns
- Regulatory changes
- Pricing pressures
- Competition from other CROs
Competitors and Market Share
Key Competitors
- IQV
- LH
- TMO
Competitive Landscape
INC Research, now Syneos Health, competes with larger CROs by offering specialized services and leveraging its global presence. It tries to differentiate itself via specialized services and speed.
Major Acquisitions
inVentiv Health
- Year: 2017
- Acquisition Price (USD millions): 0
- Strategic Rationale: The merger created a full-service biopharmaceutical solutions organization with a broader range of capabilities and scale.
Growth Trajectory and Initiatives
Historical Growth: INC Research grew organically and through acquisitions before the merger.
Future Projections: Not applicable since it is pre-merger.
Recent Initiatives: Before the merger, INC Research focused on expanding its therapeutic area expertise and geographic presence.
Summary
INC Research Holdings Inc., prior to merging with inVentiv Health to form Syneos Health, was a mid-sized CRO with strengths in specific therapeutic areas and established biopharmaceutical relationships. The merger aimed to create a larger, more comprehensive solutions provider. However, it faces competitive pressure from larger CROs and integration challenges. Its success is now tied to Syneos Health's performance.
Similar Stocks
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Press Releases
- Industry Reports
- Analyst Reports
Disclaimers:
The data provided is based on available information and may be subject to change. Market share data is approximate and may vary depending on the source. This analysis is for informational purposes only and should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About INC Research Holdings Inc
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2014-11-07 | CEO & Chairman Mr. Alexander Rabinovich | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 320 | Website https://www.intercure.co |
Full time employees 320 | Website https://www.intercure.co | ||
InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, marketing, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in the biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.